XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.16 and traded as low as $2.56. XTL Biopharmaceuticals shares last traded at $2.6450, with a volume of 54,162 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research note on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on XTLB
XTL Biopharmaceuticals Trading Up 1.6%
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Recommended Stories
- Five stocks we like better than XTL Biopharmaceuticals
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
